Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCIg versus IVIg replacement therapy in chronic lymphocytic leukaemia
ACTRN12617001008314Phase 4Terminated
- Sponsor
- Professor Stephen Mulligan
- Start
- Sep 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of polyvalent human immunoglobulin and immune globulin in hypogammaglobulinemia and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (3 arms), sponsored by Professor Stephen Mulligan. Primary endpoint: Maintenance of trough total serum IgG. Started Sep 2017; status: terminated.
02
Drugs
polyvalent human immunoglobulinimmune globulin
03
Conditions
hypogammaglobulinemiachronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ACTRN12617001008314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001008314.